drugset / Trial / NCT02213133
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have relapsed or have metastasis following chemotherapy.
Timeline
- Start
- 2014-09-22
- Primary completion
- 2015-12-10
- Completion
- 2015-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Subject | Selinexor | Other / unclassified | 80 mg | Oral |
| Subject | Selinexor | Other / unclassified | 100 mg | Oral |
| Subject | Selinexor | Other / unclassified | 120 mg | Oral |